| The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, JG Valero, A Chamorro-Jorganes, D Gonzalez, ... Oncogene 37 (14), 1830-1844, 2018 | 87 | 2018 |
| Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells S Body, A Esteve-Arenys, H Miloudi, C Recasens-Zorzo, G Tchakarska, ... Scientific reports 7 (1), 13946, 2017 | 48 | 2017 |
| ZEB1-induced tumourigenesis requires senescence inhibition via activation of DKK1/mutant p53/Mdm2/CtBP and repression of macroH2A1 O De Barrios, B Győrffy, MJ Fernández-Aceñero, E Sánchez-Tilló, ... Gut 66 (4), 666-682, 2017 | 47 | 2017 |
| Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma C Recasens-Zorzo, T Cardesa-Salzmann, P Petazzi, L Ros-Blanco, ... haematologica 104 (4), 778, 2019 | 23 | 2019 |
| Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma P Balsas, A Esteve-Arenys, J Roldán, L Jiménez, V Rodríguez, JG Valero, ... Journal of Hematology & Oncology 10, 1-14, 2017 | 17 | 2017 |
| Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma E Höring, A Montraveta, S Heine, M Kleih, L Schaaf, MC Vöhringer, ... British journal of haematology 177 (4), 557-561, 2017 | 17 | 2017 |
| Binge ethanol drinking during adolescence modifies cocaine responses in mice A Esteve-Arenys, I Gracia-Rubio, L Cantacorps, OJ Pozo, J Marcos, ... Journal of psychopharmacology 31 (1), 86-95, 2017 | 10 | 2017 |
| BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, G Roue Oncoscience 5 (3-4), 59, 2018 | 8 | 2018 |
| A mouse model of disseminated mantle cell lymphoma highlights a lack of activity of estrogen receptor β agonists toward tumor burden S Body, A Esteve-Arenys, C Recasens-Zorzo, X Troussard, G Roué, ... Leukemia & lymphoma 59 (7), 1726-1729, 2018 | 3 | 2018 |
| Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance in MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, J Garcia-Valero, D Gonzalez, A Chamorro-Jorganes, ... Cancer Research 77 (13_Supplement), 2161-2161, 2017 | 2 | 2017 |
| The BET Inhibitor GS-626510 Converges with Idelalisib through the Inhibition of Tumor-Macrophage Crosstalk and Cytokine Production in Diffuse Large B-Cell Lymphoma JG Valero, A Chamorro-Jorganes, K Walker, M Guerrero-Hernandez, ... Blood 130, 4108, 2017 | 1 | 2017 |
| Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the in vitro and in vivo activity of the BET bromodomain inhibitor CPI203 in … C Recasens-Zorzo, T Cardesa-Salzmann, L Ros-Blanco, A Esteve-Arenys, ... Cancer Research 77 (13_Supplement), 2169-2169, 2017 | 1 | 2017 |
| Innovative targeted therapies for chemorefractory B-cell non-Hodgkin lymphomas A Esteve Arenys Universitat de Barcelona, 2017 | | 2017 |
| Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma JI Borrell Bilbao, J Teixidó i Closa, R Puig de la Bellacasa Cazorla, ... Journal of Hematology & Oncology. Vol. 10, n. 80 (2017), 2017 | | 2017 |
